CD8A and neoplasm: IRE/anti-CTLA-4: 0%/15% CR. IRE + anti-CTLA-4: 46% CR Increased number of CD8+ T cells both locally and systemically compared to IRE or anti-CTLA-4. IRE + anti-CTLA-4, and subsequent anti-PD-1: Sustained tumor regression after CR.